Kinpeygo
What Kinpeygo is used for
Kinpeygo is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Kinpeygo
- Active substance
- budesonide
- Disease area
- Glomerulonephritis, IGA
- Medicine group
- Antidiarrheals, intestinal antiinflammatory / antiinfective agents
- ATC code
- A07EA06
- Marketing authorisation holder
- Stada Arzneimittel AG
- Authorised in the EU since
- 2022
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kinpeygo used for?
Kinpeygo is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g).
What is the active substance in Kinpeygo?
Kinpeygo contains budesonide.
Who makes Kinpeygo?
The EU marketing authorisation holder is Stada Arzneimittel AG.
Is Kinpeygo an orphan medicine?
Yes. Kinpeygo is designated an orphan medicine in the EU, for a rare disease (Glomerulonephritis, IGA).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU